Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8904191rdf:typepubmed:Citationlld:pubmed
pubmed-article:8904191lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8904191lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8904191lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:8904191lifeskim:mentionsumls-concept:C0042974lld:lifeskim
pubmed-article:8904191lifeskim:mentionsumls-concept:C0042971lld:lifeskim
pubmed-article:8904191lifeskim:mentionsumls-concept:C0534191lld:lifeskim
pubmed-article:8904191lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:8904191lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:8904191lifeskim:mentionsumls-concept:C0593103lld:lifeskim
pubmed-article:8904191pubmed:dateCreated1997-2-19lld:pubmed
pubmed-article:8904191pubmed:abstractTextTwo siblings affected by type III von Willebrand's disease with precipitating alloantibodies against von Willebrand's factor (vWF) and not susceptible to treatment with factor VIII/vWF concentrates received recombinant activated factor VII for oral surgery. This therapy, combined with antifibrinolytic drugs and local application of fibrin glue, seems to be effective and safe. It may be considered a promising approach to the management of this rare condition.lld:pubmed
pubmed-article:8904191pubmed:languageenglld:pubmed
pubmed-article:8904191pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8904191pubmed:citationSubsetIMlld:pubmed
pubmed-article:8904191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8904191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8904191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8904191pubmed:statusMEDLINElld:pubmed
pubmed-article:8904191pubmed:issn0301-0147lld:pubmed
pubmed-article:8904191pubmed:authorpubmed-author:CiavarellaNNlld:pubmed
pubmed-article:8904191pubmed:authorpubmed-author:ManginiFFlld:pubmed
pubmed-article:8904191pubmed:authorpubmed-author:SchiavoniMMlld:pubmed
pubmed-article:8904191pubmed:authorpubmed-author:InchingoloFFlld:pubmed
pubmed-article:8904191pubmed:authorpubmed-author:ValenzanoEElld:pubmed
pubmed-article:8904191pubmed:issnTypePrintlld:pubmed
pubmed-article:8904191pubmed:volume26 Suppl 1lld:pubmed
pubmed-article:8904191pubmed:ownerNLMlld:pubmed
pubmed-article:8904191pubmed:authorsCompleteYlld:pubmed
pubmed-article:8904191pubmed:pagination150-4lld:pubmed
pubmed-article:8904191pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:meshHeadingpubmed-meshheading:8904191-...lld:pubmed
pubmed-article:8904191pubmed:year1996lld:pubmed
pubmed-article:8904191pubmed:articleTitleUse of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor.lld:pubmed
pubmed-article:8904191pubmed:affiliationServizio di Coagulazione, Centro Emofilia, Policlinico-Universita, Bari, Italy.lld:pubmed
pubmed-article:8904191pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8904191pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8904191lld:pubmed